Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Artiva Biotherapeutics, Inc.

NASDAQ: ARTV · Life Sciences · 10 alerts · CIK 1817241

Share price
$3.96Close, Nov 16
Market cap
$196M
Shares outstanding
49.43MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Artiva Biotherapeutics, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K/A
Business Update

Artiva Biotherapeutics Business Update

Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.

8:30 AM ET 8-K
Business Update

Artiva Biotherapeutics Business Update

Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.